Yesterday evening, the SCOR Group was awarded the “Prix de la meilleure opération financière – M&A” (Prize for the Best Financial Operation) for 2013 by the Club des Trente, for its acquisition of Generali US.
SCOR's first quarter of 2014 results.
All the proposed resolutions were adopted by SCOR’s shareholders by a very large majority, including payment of a dividend of EUR 1.30 per share for the 2013 financial year.
SCOR Global Life's embedded value results of 2013.
SCOR delivers a strong performance for the first quarter 2014 with a net income of EUR 135 million, up 21.6%
The SCOR Global P&C 1 April renewals lead to premium growth of 8.5% with expected profitability well within targets
The SCOR Global P&C 1 April renewals lead to premium growth of 8.5% with expected profitability well within targets
The SCOR Global P&C 1 April renewals lead to premium growth of 8.5% with expected profitability well within targets.
The pharmaceutical industry has been actively seeking the ideal treatment for hepatitis C for years: a treatment whose features would be an eradication of the virus from the body in 100% of cases.
The pharmaceutical industry has been actively seeking the ideal treatment for hepatitis C for years: a treatment whose features would be an eradication of the virus from the body in 100% of cases.
In 2013, an innovative neurology is emerging which is overcoming all kinds of hurdles: genetics, biotechnology, medical imaging, neurosurgery, the pharmaceutical industry… fundamental and clinical research are uniting
In December 2013 the Critical Illness Defi nitions and Geographical Variations Working Party presented their paper, ‘Extending the Critical Path’ to the Staple Inn Actuarial Society.
